期刊文献+

血清CEA、CA242和PET/CT显像联合检测对胰腺癌的诊断价值 被引量:9

The Diagnostic Value of Serum CEA、CA242 and PET/CT Imaging in Pancreatic Cancer
在线阅读 下载PDF
导出
摘要 目的 探究血清癌胚抗原(CEA)、糖链抗原242(CA242)及计算机断层扫描(PET/CT)联合检测对胰腺癌的诊断价值。方法 回顾性选取2016年6月至2020年10月拟诊断为胰腺癌的患者106例为研究对象。所有患者均术前进行血清CEA、CA242检测及PET/CT显像检查,分析血清CEA、CA242与PET/CT显像联合检测对胰腺癌患者的临床诊断价值。结果 106例拟诊断为胰腺癌的患者行手术病理显示胰腺癌患者88例,胰腺良性疾病者18例。胰腺癌组血清CEA、CA242水平分别为(^(18).58±5.69)ng/mL、(41.55±14.42)U/mL,均高于胰腺良性组的(10.92±2.24)ng/mL、(^(18).68±6.25)U/mL (P<0.05)。PET/CT影像显示胰腺癌患者病灶可见^(18)F-FDG代谢增加,且病变局部放射性浓集明显增高,胰腺良性疾病中显示病变局部放射性浓集不增高或轻微增高。PET/CT影像检查诊断胰腺癌的敏感度、特异度、准确度分别为88.6%、77.8%、86.79%,血清CEA诊断胰腺癌的敏感度、特异度、准确度为84.1%、66.7%、81.13%,血清CA242诊断胰腺癌的敏感度、特异度、准确度为85.2%、72.2%、83.02%,联合检测诊断胰腺癌的敏感度、特异度、准确度为95.5%、94.4%、95.28%,均高于单项检测。结论 血清CEA、CA242和PET/CT显像联合检测对胰腺癌的诊断价值高。 Objective To investigate the diagnostic value of serum carcinoembryonic antigen(CEA), sugar chain antigen 242(CA242) and computed tomography(PET/CT) in pancreatic cancer. Methods From June 2016 to October 2020,106 patients with pancreatic cancer were selected as the subjects. Serum CEA, CA242 and PET/CT imaging were performed in all patients before operation to analyze the clinical diagnostic value of serum CEA、CA242 level and PET/CT imaging in pancreatic cancer patients. Results Surgical pathology of 106 patients with pancreatic cancer, There were 18 cases of benign pancreatic diseases. Serum CEA、CA242 levels in pancreatic cancer group were(18.58±5.69)ng/mL、(41.55±14.42)U/mL, respectively were higher than those in the benign group of pancreas(10.92±2.24)ng/mL,(^(18).68±6.25)U/mL(P<0.05). PET/CT images showed that ^(18)F-FDG of metabolism increased in pancreatic cancer patients, and the local radioactivity concentration was significantly increased, and the local radioactivity concentration was not increased or slightly increased in benign pancreatic diseases. PET/CT sensitivity, specificity and accuracy were 88.6%, 77.8% and 86.79% respectively, Serum CEA sensitivity, specificity and accuracy were 84.1%, 66.7%, 81.13%, Serum CA242 sensitivity, specificity and accuracy were 85.2%, 72.2%, 83.02%, The sensitivity, specificity and accuracy of the combined detection were 95.5%, 94.4%, 95.28%, All were higher than single test. Conclusion The combined detection of serum CEA, CA242 and PET/CT imaging has high diagnostic value for pancreatic cancer.
作者 李林 毛朝明 司马玉洁 牟笑 周建明 LI Lin;MAO Zhao-ming;SIMA Yu-jie;MOU Xiao;ZHOU Jian-ming(Department of Nuclear Medicine,Affiliated Hospital of Jiangsu University,Zhenjiang 212000,Jiangsu Province,China)
出处 《中国CT和MRI杂志》 2023年第1期115-116,185,共3页 Chinese Journal of CT and MRI
关键词 胰腺癌 癌胚抗原 糖链抗原242 计算机断层扫描 诊断价值 Pancreatic Cancer Carcinoembryonic Antigen Sugar Chain Antigen 242 Computed Tomography Diagnostic Value
  • 相关文献

参考文献17

二级参考文献134

  • 1Liao, Quan,Zhao, Yu-Pei,Yang, Ying-Chi,Li, Li-Jun,Long, Xiao,Han, Shao-Mei.Combined detection of serum tumor markers for differential diagnosis of solid lesions located at the pancreatic head[J].Hepatobiliary & Pancreatic Diseases International,2007,6(6):641-645. 被引量:27
  • 2王中秋,卢光明,郑玲,朱虹,常林风,吴江,秦莉萍.PET/CT及其他影像手段对胰腺癌诊断的比较研究[J].医学影像学杂志,2006,16(1):84-87. 被引量:17
  • 3Callery MP,Chang KJ,Fishman EK,et al.Pretreatment assessment of resectable and borderline resectable pancreatic cancer:expert consensus statement.Ann Surg Oncol,2009,16:1727-1733.
  • 4Katz MH,Pisters PW,Evans DB,et al.Borderline resectable pancreatic cancer:the importance of this emerging stage of disease.J Am Coll Surg,2008,206:833-846.
  • 5Gillen S,Schuster T,Meyer Zum Büschenfelde C,et al.Preoperative/neoadjuvant therapy in pancreatic cancer:a systematic review and meta-analysis of response and resection percentages.PLoS Med,2010,7:e1000267.
  • 6Hidalgo M.Pancreatic cancer.N Engl J Med,2010,362:1605-1617.
  • 7Müller SA,Hartel M,Mehrabi A,et al.Vascular resection in pancreatic cancer surgery:survival determinants.J Gastrointest Surg,2009,13:784-792.
  • 8Tseng JF,Raut CP,Lee JE,et al.Pancreaticoduodenectomy with vascular resection:margin status and survival duration.J Gastrointest Surg,2004,8:935-949.
  • 9Conroy T,Desseigne F,Ychou M,et al.Randomized phase Ⅲ trial comparing FOLFIRINOX (F:5FU/leucovorin[LV] ,irinotecan[I] ,andoxaliplatin[O] ) versus gemcitabine (G) as first-line treatment for metastaticpancreatic adenocarcinoma (MPA):Preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial.J Clin Oncol,2010,28:4010.
  • 10Neoptolemos JP,Stocken DD,Bassi C,et al.Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection:a randomized controlled trial.JAMA,2010,304:1073-1081.

共引文献119

同被引文献107

引证文献9

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部